Piramal Pharma launches new concentration of Zinc Sulfate for Injection in U.S.

The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio

Piramal Pharma Solutions commissions ADC manufacturing expansion in Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site

Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening

USFDA inspection at Piramal Pharma’s Bethlehem facility

Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr

The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023

SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue

Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders

Piramal Pharma posts Q4 FY23 consolidated PAT at Rs. 50.11 Cr

The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023

Piramal Pharma starts production at new API facility in Riverview, Michigan

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)

Briefs: Piramal Pharma, Alembic Pharmaceuticals

USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA

USFDA conducts PAI and GMP inspection of Piramal Pharma's Sellersville facility

The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations